|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on january 15, 2019.Upon further investigation of the reported event, the following information is new and/or changed: additional device information - added exp date; date received by manufacturer; indication that this is a follow-up report; follow-up due to additional information and device evaluation; device evaluated by manufacturer; device manufacture date; identification of evaluation codes 10, 11, 3331, 213, 22.Method code #1: 10 - testing of actual/suspected device; method code #2: 11 - testing of device from same lot/batch retained by manufacturer; method code #3: 3331 - analysis of production records; results code: 213 - no device problem found; conclusions code: 22 - known inherent risk of device.The returned sample was visually inspected, during which no anomalies were noted anywhere on the device.The sample was built into a saline circuit and then set up on a sarns drive motor.The rpm were set at 900 and ramped up by 300 rpm every ten minutes for one hour for a maximum of 2400 rpm.During each interval, the returned sample was observed for any running sound anomalies.No sound anomalies or abnormalities with the functionality of the pump were observed during the test.A retention sample from the affected product code/lot number was obtained and tested the same way, no sound anomalies noted either.The noise was not able to be replicated on the complaint sample ; however, the issue experienced by the customer is likely due to an abnormal interaction between the seal rotor and stator surfaces.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|